Table 2:
Characteristics of included studies
| First Author,Publication Year | Region | No. of Cases | Median/Mean Age | Tumor Grade n | Field Strength | Perfusion Technique | Diagnostic Parameters |
|---|---|---|---|---|---|---|---|
| Dallery, 2017 | France | 30 | 9.4 | 11 LG, 19 | 1.5 & 3T | DSC | rCBF, rCBV |
| HG | GE | ||||||
| Dangouloff-Ros, 2016 | France | 117 | 6.2 | 52 LG, 65 | 1.5T GE | ASL | rCBF |
| HG | |||||||
| Hales, 2019 | UK | 32 | 4.5 | 13 LG, 19 | 1.5 & 3T | ASL | rCBF |
| HG | Siemens | ||||||
| Ho, 2015 | USA | 63 | 6.3 | 38 LG, 25 | 1.5 & 3T | DSC | rCBV |
| HG | Siemens | ||||||
| Kikuchi, 2017 | Japan | 19 | 6 | 11 LG, 8 HG | 3T Philips | ASL | rCBF |
| Morana, 2017 | Italy | 26 | 9.5 | 12 LG, 14 | 1.5T | ASL | rCBF |
| HG | Philips | ||||||
| Morana, 2018 | Italy | 37 | 9 | 22 LG, 15 | 1.5T | ASL & DSC | rCBF, rCBV |
| HG | Philips | ||||||
| Piccardo, 2019 | Italy | 22 | 9 | 10 LG, 12 | 1.5T | ASL | rCBF |
| HG | Philips | ||||||
| Testud, 2021 | France | 46 | 7 | 15 LG, 31 | 1.5 & 3T | ASL & DSC | rCBF, rCBV |
| HG | Siemens | ||||||
| Withey, 2022 | UK | 85 | 8 | 45 LG, 40 | 1.5 & 3T | DSC | rCBV |
| HG | Various |